Could a Bone-Seeking radiation drug catch prostate cancer early?
NCT ID NCT04206319
First seen Nov 01, 2025 · Last updated Jun 05, 2026 · Updated 32 times
Summary
This study tests Radium-223 in men whose prostate cancer has returned after initial treatment, but only shows up as rising PSA levels in blood—not on standard scans. The goal is to see how the drug affects the immune system and PSA levels. Participants receive up to 6 doses of Radium-223 and are followed for life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIOCHEMICAL RECURRENT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.